226 related articles for article (PubMed ID: 21215092)
21. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.
Tomita T
Bosn J Basic Med Sci; 2020 Aug; 20(3):336-346. PubMed ID: 32020844
[TBL] [Abstract][Full Text] [Related]
22. Preface: Gastroenteropancreatic system and its tumors: Part 1.
Vinik AI
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xvii-xviii. PubMed ID: 21095538
[No Abstract] [Full Text] [Related]
23. [Diagnostic criteria and classification of gastro-intestinal pancreatic endocrine tumors].
Capella C; Uccella S; Albarello L; Feltri M; La Rosa S
Minerva Endocrinol; 2001 Sep; 26(3):103-10. PubMed ID: 11753231
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
26. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
27. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
28. [Neuroendocrine tumors of the gastrointestinal tract].
Klöppel G
Pathologe; 2003 Jul; 24(4):287-96. PubMed ID: 14513276
[TBL] [Abstract][Full Text] [Related]
29. [Gastroenteropancreatic neuroendocrine neoplasms. Role of biopsies].
Bergmann F
Pathologe; 2013 Nov; 34 Suppl 2():221-5. PubMed ID: 24196617
[TBL] [Abstract][Full Text] [Related]
30. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
31. Pathology.
Scoazec JY; Couvelard A; Leteurtre E; Terris B;
Ann Endocrinol (Paris); 2013 Jul; 74(3):203-6. PubMed ID: 23768679
[No Abstract] [Full Text] [Related]
32. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
[TBL] [Abstract][Full Text] [Related]
33. Classification of neuroendocrine tumours.
Klöppel G; Solcia E; Capella C; Heitz PU
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S111-6. PubMed ID: 10604114
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
35. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids.
Jakobsen AM; Ahlman H; Kölby L; Abrahamsson J; Fischer-Colbrie R; Nilsson O
Br J Cancer; 2003 Jun; 88(11):1746-54. PubMed ID: 12771991
[TBL] [Abstract][Full Text] [Related]
36. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors.
Rindi G; Capella C; Solcia E
J Mol Med (Berl); 1998 May; 76(6):413-20. PubMed ID: 9625298
[TBL] [Abstract][Full Text] [Related]
37. [Introduction of 2010 WHO classification of pancreatic tumors].
Chang XY; Chen J
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):423-5. PubMed ID: 24060084
[No Abstract] [Full Text] [Related]
38. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
[TBL] [Abstract][Full Text] [Related]
39. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology.
Chatzipantelis P; Konstantinou P; Kaklamanos M; Apostolou G; Salla C
Cancer; 2009 Jun; 117(3):211-6. PubMed ID: 19350669
[TBL] [Abstract][Full Text] [Related]
40. CD200 Expression in Neuroendocrine Neoplasms.
Love JE; Thompson K; Kilgore MR; Westerhoff M; Murphy CE; Papanicolau-Sengos A; McCormick KA; Shankaran V; Vandeven N; Miller F; Blom A; Nghiem PT; Kussick SJ
Am J Clin Pathol; 2017 Sep; 148(3):236-242. PubMed ID: 28821198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
